Control of coronary risk factors in secondary prevention: PRESENAP study;Control de factores de riesgo coronario en prevención secundaria: Estudio PRESENAP

Medicina Clinica

Volumn 127, Issue 20, 2006, Pages 765-769

  Iparraguirre, Salvador Tranche ^a   Rodríguez, Isidro López ^b   Prieto, José María Mostaza ^c   López, Begoña Soler ^d   Morató, María Teresa Mantilla ^e   Taboada, Manuel Taboada ^f   Rallo, Carlos Lahoz ^c   Martín Jadraque, Luís ^c   Monteiro, Beatriz ^g  

^a Centro de Salud El Cristo   (Spain)

^b Centro de Salud de Begonte   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d CRO E C BIO   (Spain)

^e Centro de Salud Mar Baltico   (Spain)

^f Centro de Salud Fuencarral   (Spain)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Coronary disease; Primary care; Risk factors; Secondary prevention

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CONTROL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; REVASCULARIZATION; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING HABIT; ST SEGMENT ELEVATION;

EID: 33846352567     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095812     Document Type: Article

References (25)

1. Instituto Nacional de Estadística [citado 27 Dic 2005]. Disponible en: http://www.ine.es/inebase
2. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med. 2002;162:2405-10.
3. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999. The Framingham Heart Study. Circulation. 2004;110:522-7.
4. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischemic heart disease: nested case-control analysis. BMJ. 2005;330:1059-63.
5. Clark A, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronaty artery disease. Ann Intern Med. 2005;143:659-72.
6. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1998;19:1434-503.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-10.
8. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-9.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J. 2001;2:554-72.
10. De Velasco JA, Cosín J, López-Sendón JL, De Teresa E, De Oya M, Carrasco JL, et al, en nombre del grupo de investigadores del estudio PREVESE. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol. 1997;50:406-15.
11. De Velasco JA, Cosin J, López-Sendón JL, De Teresa E, De Oya M, Sellers G, en nombre del grupo de investigadores del estudio PREVESE II. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II. Rev Esp Cardiol. 2002;55:601-9.
12. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Arch Intern Med. 2001;161:1621-8.
13. Brotons C, Permanyer G, Pacheco V, Moral I, Ribera A, Gascant P, et al. Prophylactic treatment after myocardial infarction in primary care: how far can we go? Fam Practice. 2003;20:32-5.
14. Bhatt DL, Steg PG, Ohman EM, Hirsh AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-9.
15. Underwood PM, Cozma LS, Laji K, Cohen H, Oboubie K, Beck P. Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction. Heart. 2004;90:1332-3.
16. Vale MJ, Jelinek MV, Best JD; on behalf of the COACH study group. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust. 2002;176:211-5.
17. McLeod AL, Brooks L, Taylor V, Currie PF, Dewhurst NG. Secondary prevention for coronary artery disease. QJM. 2004;97:127-31.
18. El-Jack S, Kerr A. Secondary prevention in coronary disease patients in South Auckland: moving targets and the current treatment gap. New Z Med J. 2003;116:664-71.
19. De la Peña A, Suárez C, Cuende I, Muñoz M, Garré J, Camafort M, et al. Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España. Estudio CIFARC. Med Clin (Barc). 2005;124:44-9.
20. Danchin N, Grenier O, Ferrières J, Cantet C, Cambou J-P. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart. 2002;88:159-62.
21. Hanratty B, Lawlor DA, Robinson MB, Sapsford RJ, Greenwood D, Hall A. Sex differences in risk factors, treatment and mortality after acute myocardial infarction: an observational study. J Epidemiol Community Health. 2000;54:912-6.
22. Rosengren A, Wallentin L, Gitt AK, Behar S, Battier A, Hasdal D. Sex, age, and clinical presentation of acute coronary syndromes. Eur Heart J. 2004;25:663-70.
23. Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. Am J Manage Care. 2004;10:383-91.
24. Majumdar SR, McAlister A, Furberg CD. From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol. 2004;43:1738-42.
25. Álvarez-Sala LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al. Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria. Med Clin (Barc). 2005;124:406-10.